Home/Pipeline/Erdafitinib

Erdafitinib

Urothelial Carcinoma

Phase 3Active

Key Facts

Indication

Urothelial Carcinoma

Phase

Phase 3

Status

Active

Company

Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Cardiopulmonary Cardiovascular Orthopaedics Surgery Vision

Other Urothelial Carcinoma Drugs

Drug	Company	Phase	Status
Enfortumab vedotin	Astellas	Phase 3	Active (Combination Trials)
Urothel PD-L1	Mindpeak	Commercial	Active
UGN-501	UroGen Pharma	Preclinical	Active